Diagnosis and therapy of antiphospholipid syndrome

Polskie Archiwum Medycyny Wewnetrznej

Volumn 125, Issue 9, 2015, Pages 672-677

  Pengo, Vittorio ^a   Denas, Gentian ^a   Padayattil, Seena J ^a   Zoppellaro, Giacomo ^a   Bison, Elisa ^a   Banzato, Alessandra ^a   Hoxha, Ariela ^a   Ruffatti, Amelia ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Antiphospholipid syndrome; Diagnosis; Pregnancy; Review; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; BETA2 GLYCOPROTEIN 1 ANTIBODY; CLOPIDOGREL; HEPARIN; IMMUNOGLOBULIN; PHOSPHOLIPID ANTIBODY; PREDNISOLONE; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; DEEP VEIN THROMBOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LABORATORY DIAGNOSIS; LUNG EMBOLISM; PLASMAPHERESIS; PREGNANCY OUTCOME; PREGNANT WOMAN; REVIEW; SECONDARY PREVENTION; THROMBOSIS PREVENTION; TREATMENT DURATION; FEMALE; MIDDLE AGED; PREGNANCY;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; MIDDLE AGED; PREGNANCY;

EID: 84943617411     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.3051     Document Type: Review

References (66)

1. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthr Rheum. 1999; 42: 1309-1311.
2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4: 295-306.
3. Pengo V, Biasiolo A, Pegoraro C, et al. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost. 2005; 93: 1147-1152.
4. Pengo V, Biasiolo A, Gresele P, et al. A comparison of lupus anticoagulant-positive patients with clinical picture of antiphospholipid syndrome and those without. Arterioscler Thromb Vasc Biol. 2007; 27: e309-e310.
5. de Groot PG, Lutters B, Derksen RH, et al. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost. 2005; 3: 1993-1997.
6. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the an-tiphospholipid syndrome: a systematic review of the literature. Blood. 2003; 101: 1827-1832.
7. Pengo V, Testa S, Martinelli I, et al. Incidence of a first thromboembol-ic event in carriers of isolated lupus anticoagulant. Thromb Res. 2015; 135: 46-49.
8. Ruffatti A, Olivieri S, Tonello M, et al. Influence of different IgG anticar-diolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost. 2008; 6: 1693-1696.
9. Runchey SS, Folsom AR, Tsai M Y, et al. Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study. Br J Haematol. 2002; 119: 1005-1010.
10. Proven A, Bartlett R P, Moder KG, et al. Clinical importance of positive test results for lupus anticoagulant and anticardiolipin antibodies. Mayo Clin Proc. 2004; 79: 467-475.
11. Rampazzo P, Biasiolo A, Garin J, et al. Some patients with antiphospho-lipid syndrome express hitherto undescribed antibodies to cardiolipin-bind-ing proteins. Thromb Haemost. 2001; 85: 57-62.
12. Urbanus RT, Siegerink B, Roest M, et al. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol. 2009; 8: 998-1005.
13. de Laat B, Pengo V, Pabinger I, et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost. 2009; 7: 1767-1773.
14. Pengo V, Biasiolo A, Gresele P, et al; Participating Centres of Italian Federation of Thrombosis Centres (FCSA). Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. J Thromb Haemost. 2007; 5: 925-930.
15. Tripodi A, Biasiolo A, Chantarangkul V, Pengo V. Lupus anticoagulant (LA) testing: performance ofclinical laboratories assessed by a national survey using lyophilized affinity-purified immunoglobulin with LA activity. Clin Chem. 2003; 49: 1608-1614.
16. Pengo V, Biasiolo A, Bison E, et al; Italian Federation of Anticoagula-tion Clinics (FCSA). Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-Glycoprotein I activity. Thromb Res. 2007; 120: 127-133.
17. Sailer T, Zoghlami C, Kurz C, et al. Anti-beta2 glycoprotein I antibodies are associated with pregnancy loss in women with the lupus anticoagulant. Thromb Haemost. 2006; 95: 796-801.
18. Zoghlami-Rintelen C, Vormittag R, Sailer T, et al. The presence of IgG antibodies against beta2-glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant. J Thromb Haemost. 2005; 3: 1160-1165.
19. Ruffatti A, Tonello M, Del Ross T, et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost. 2006; 96: 337-341.
20. Ruffatti A, Tonello M, Cavazzana A, et al. Laboratory classification categories and pregnancy outcome in patients with primary antiphospholip-id syndrome prescribed antithrombotic therapy. Thromb Res. 2009; 123: 482-487.
21. de Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood. 2005; 105: 1540-1545.
22. Pengo V, Balestrieri G, Tincani A, et al. Utilization of dilute Russell's viper venom time to detect autoantibodies against beta 2-glycoprotein I which express anticoagulant activity in the presence but not in the absence of exogenous phospholipids. Thromb Haemost. 1997; 77: 123-126.
23. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high risk patients diagnosed with antiphospholipid syndrome (APS). J Thromb Haemost. 2010; 8: 237-242.
24. Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembol-ic event in asymptomatic carriers of high risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011; 118: 4714-4718.
25. Pengo V, Ruffatti A, Tonello M, et al. Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk. J Thromb Haemost. 2015; 13: 782-787.
26. Pengo V, Ruffatti A, Del Ross T, et al. Confirmation of initial antiphos-pholipid antibody positivity depends on the antiphospholipid antibody profile. J Thromb Haemost. 2013; 11: 1-5.
27. Galli M, Borrelli G, Jacobsen EM, et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood. 2007; 110: 1178-1183.
28. Naess IA, Christiansen SC, Cannegieter SC, et al. A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study). J Thromb Haemost. 2006; 4: 44-49.
29. Runchey SS, Folsom AR, Tsai MY, et al. Anticardiolipin antibodies as a risk factor for venous thromboembolism in a population-based prospective study. Br J Haematol. 2002; 119: 1005-1010.
30. Pengo V, Ruffatti A, Tonello M, et al. Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles. Thromb Res. 2015; 136: 161-163.
31. Girardi G, Berman J, Redecha P, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest. 2003; 112: 1644-1654.
32. Shamonki JM, Salmon JE, Hyjek E, Baergen RN. Excessive complement activation is associated with placental injury in patients with antiphos-pholipid antibodies. Am J Obstet Gynecol. 2007; 196: 167.
33. Pengo V, Tripodi A, Reber G, et al; Subcommittee on Lupus Anticoag-ulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemosta-sis. J Thromb Haemost. 2009; 7: 1737-1740.
34. Pierangeli SS, de Groot PG, Dlott J, et al. 'Criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010. Lupus. 2011; 20: 182-190.
35. Devreese KM, Pierangeli SS, de Laat B, et al; Subcommittee on Lupus Anticoagulant/Phospholipid/Dependent Antibodies. Testing for antiphospho-lipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost. 2014; 12: 792-795.
36. Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 2007; 57: 1487-1495.
37. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003; 349: 1133-1138.
38. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005; 3: 848-853.
39. Torn M, van der Meer FJ, Rosendaal FR. Lowering the intensity of oral anticoagulant therapy: effects on the risk of hemorrhage and thromboembo-lism. Arch Intern Med. 2004; 164: 668-673.
40. Palareti G, Legnani C, Guazzaloca G, et al. Risks factors for highly unstable response to oral anticoagulation: a case-control study. Br J Haematol. 2005; 129: 72-78.
41. Albers GW, Amarenco P, Donald Easton J, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008; 133: 630S-669S.
42. Pengo V, Ruiz-Irastorza G, Denas G, et al. High intensity anticoagula-tion in the prevention of the recurrence of arterial thrombosis in antiphos-pholipid syndrome: 'PROS' and 'CONS'. Autoimmun Rev. 2012; 11: 577-580.
43. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011; 20: 206-218.
44. Urlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002; 347: 969-974.
45. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol. 1996; 174: 1584-1589.
46. Rai R, Cohen H, Dave M, et al. Randomised controlled trial of aspirin and aspirin plus in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J. 1997; 314: 253-257.
47. Franklin RD, Kutteh WH. Antiphospholipid antibodies (APA) and recurrent pregnancy loss: a unique APA positive population. Hum Reprod. 2002; 17: 2981-2985.
48. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol. 2002; 100: 408-413.
49. Laskin CA, Spitzer KA, Clark CA, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol. 2009; 36: 279-287.
50. Mak A, Cheung MW, Cheak AA, et al. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology. 2010; 9: 281-288.
51. Szodoray P, Bacskó G, Lakos G, et al. Combined therapy in pregnancy with primary antiphospholipid syndrome. Orv Hetil. 2003; 144: 2411-2413.
52. Chang P, Millar D, Tsang P, et al. Intravenous immunoglobulin in an-tiphospholipid syndrome and maternal floor infarction when standard treatment fails: a case report. Am J Perinatol. 2006; 23: 125-129.
53. Kaaja R, Julkunen H, Ammälä P, et al. Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy losses associated with antiphospholipid antibodies. Acta Obstet Gynecol Scand. 1993; 72: 63-66.
54. Branch DW, Peaceman AM, Druzin M, et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphos-pholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol. 2000; 182: 122-127.
55. Xiao J, Xiong J, Zhu F, et al. Effect of prednisone, aspirin, low molecular weight heparin and intravenous immunoglobulin on outcome of pregnancy in women with antiphospholipid syndrome. Exp Ther Med. 2013; 5: 287-291.
56. Bramham K, Thomas M, Nelson-Piercy C, et al. First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood. 2011; 117: 6948-6951.
57. Frampton G, Cameron JS, Thom M, et al. Successful removal of anti-phospholipid antibody during pregnancy using plasma exchange and low-dose prednisolone. Lancet. 1987; 2: 1023-1024.
58. El-Haieg DO, Zanati M F, El-Foual FM. Plasmapheresis and pregnancy outcome in patients with antiphospholipid syndrome. Int J Gynaecol Obstet. 2007; 99: 236-241.
59. Nakamura Y, Yoshida K, Itoh S, et al. Immunoadsorption plasmapher-esis as a treatment for pregnancy complicated by systemic lupus erythe-matosus with positive antiphospholipid antibodies. Am J Reprod Immunol. 1999; 41: 307-311.
60. Kobayashi S, Tamura N, Tsuda H, et al. Immunoadsorbent plasmapher-esis for a patient with antiphospholipid syndrome during pregnancy. Ann Rheum Dis. 1992; 51: 399-401.
61. Ruffatti A, Marson P, Pengo V, et al. Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature. Autoimmun Rev. 2007; 6: 196-202.
62. Bortolati M, Marson P, Chiarelli S, et al. Case reports of the use of immunoadsorption or plasma exchange in high-risk pregnancies of women with antiphospholipid syndrome. Ther Apher Dial. 2009; 13: 157-160.
63. Ruffatti A, Tonello M, Visentin MS, et al. Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology. 2011; 50: 1684-1689.
64. Ruffatti A, Salvan E, Del Ross T, et al. Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study. Thromb Haemost. 2014; 112: 727-735.
65. Marson P, Bagatella P, Bortolati M, et al. Plasma exchange for the management of the catastrophic antiphospholipid syndrome: importance of the type of fluid replacement. J Intern Med. 2008; 264: 201-203.
66. Ruffatti A, Marson P, Pengo V, et al. Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature. Autoimmun Rev. 2007; 6: 196-202.